Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial

Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial

Background: Preclinical studies recently showed that the mineralocorticoid antagonist spironolactone acts also as an antagonist of the NRG1-ERBB4 signaling pathway and improves schizophrenia-like behaviour in Nrg1 transgenic mouse model. As this signaling pathway is critically linked to the pathophy...

Full description

Bibliographic Details
Main Authors: Alkomiet Hasan, Astrid Roeh, Stefan Leucht, Berthold Langguth, Maximilian Hansbauer, Tatiana Oviedo-Salcedo, Sophie K. Kirchner, Irina Papazova, Lisa Löhrs, Elias Wagner, Isabel Maurus, Wolfgang Strube, Moritz J. Rossner, Michael C. Wehr, Ingrid Bauer, Stephan Heres, Claudia Leucht, Peter M. Kreuzer, Stephanie Zimmermann, Thomas Schneider-Axmann, Thomas Görlitz, Susanne Karch, Silvia Egert-Schwender, Beate Schossow, Philipp Rothe, Peter Falkai
Format: Article
Language:English
Published: Elsevier 2020-03-01
Series:Contemporary Clinical Trials Communications
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865420300211

Internet

http://www.sciencedirect.com/science/article/pii/S2451865420300211

Similar Items